GH Research (NASDAQ:GHRS) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of GH Research (NASDAQ:GHRS) from a hold rating to a sell rating in a research report sent to investors on Thursday.

A number of other equities research analysts have also recently commented on GHRS. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research note on Friday, May 9th. Cantor Fitzgerald raised GH Research to a “strong-buy” rating in a research note on Tuesday, May 13th. Guggenheim reduced their price objective on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Royal Bank of Canada assumed coverage on GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 price objective for the company. Finally, Stifel Nicolaus raised their price objective on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.43.

GH Research Stock Performance

Shares of GHRS stock opened at $11.27 on Thursday. The company has a market cap of $586.36 million, a P/E ratio of -14.27 and a beta of 0.86. The stock has a 50 day simple moving average of $10.34 and a two-hundred day simple moving average of $10.03. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.42. On average, research analysts predict that GH Research will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GHRS. Geode Capital Management LLC boosted its position in shares of GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after buying an additional 3,092 shares during the last quarter. Diadema Partners LP purchased a new position in shares of GH Research during the fourth quarter valued at approximately $711,000. Lynx1 Capital Management LP boosted its position in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after buying an additional 663,100 shares during the last quarter. Northern Trust Corp boosted its position in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after buying an additional 8,641 shares during the last quarter. Finally, AdvisorShares Investments LLC boosted its position in shares of GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after buying an additional 4,806 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).